Sinocelltech Group (688520) Stock Overview
A biopharmaceutical company, engages in the research, development, and production of recombinant proteins, antibody drugs, and vaccines in China. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Risk Analysis
No risks detected for 688520 from our risk checks.
688520 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
The Market Is Sleeping on This Parkinson's Biotech - And I Think That's a Mistake
Gain Therapeutics: The Under-the-Radar Biotech With Big Parkinson’s Potential Key Takeaways Gain Therapeutics (GANX) is developing GT-02287 – an oral, first-in-class, potentially disease-modifying treatment for Parkinson’s disease targeting the GCase enzyme pathway. Parkinson’s disease represents a $4 billion U.S. market with zero approved disease-modifying therapies.
Read full narrativeSinocelltech Group Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥41.18 |
| 52 Week High | CN¥89.04 |
| 52 Week Low | CN¥35.69 |
| Beta | 0.73 |
| 1 Month Change | -1.18% |
| 3 Month Change | 5.86% |
| 1 Year Change | 12.82% |
| 3 Year Change | -36.80% |
| 5 Year Change | -7.46% |
| Change since IPO | -43.64% |
Recent News & Updates
Shareholder Returns
| 688520 | CN Biotechs | CN Market | |
|---|---|---|---|
| 7D | 0.8% | -0.9% | 1.2% |
| 1Y | 12.8% | 1.2% | 35.8% |
Return vs Industry: 688520 exceeded the CN Biotechs industry which returned 1.2% over the past year.
Return vs Market: 688520 underperformed the CN Market which returned 35.8% over the past year.
Price Volatility
| 688520 volatility | |
|---|---|
| 688520 Average Weekly Movement | 6.2% |
| Biotechs Industry Average Movement | 5.6% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in CN Market | 9.7% |
| 10% least volatile stocks in CN Market | 4.1% |
Stable Share Price: 688520 has not had significant price volatility in the past 3 months compared to the CN market.
Volatility Over Time: 688520's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2007 | 2,242 | Liangzhi Xie | www.sinocelltech.com |
Sinocelltech Group Limited, a biopharmaceutical company, engages in the research, development, and production of recombinant proteins, antibody drugs, and vaccines in China. The company offers Anjiayin, a third-generation recombinant coagulation factor VIII product for the treatment of hemophilia A; Anpingxi, an anti-CD20 monoclonal antibody for the treatment of CD20-positive diffuse large B-cell non-Hodgkin's lymphoma; Anjiarun, an adalimumab biosimilar for the treatment of various autoimmune diseases; Anbezu, a bevacizumab biosimilar for the treatment of various solid tumors; SCTV01, a series of recombinant protein vaccines for multiple variants of the new coronavirus; Fenolimab, a recombinant humanized anti-PD-1 monoclonal antibody for the treatment of solid tumors; and SCT1000, a recombinant 14-valent human papillomavirus (HPV) virus-like particle vaccine for the prevention of various cancers. It also develops other clinical-stage products, including SCT650C for the treatment of plaque psoriasis, axial spondylarthritis, and other autoimmune diseases; SCTC21C for the treatment of CD38-positive blood cancers; SCTB35 for the treatment of diseases, such as CD20-positive B-cell non-Hodgkin's lymphoma; SCTB14 for immunotherapy of multiple solid tumors; SCTB41 for multiple solid tumor immunotherapy; SCTV02 to prevent respiratory diseases; SCTV04C to prevent herpes zoster; SCT520FF, an anti-angiogenic biopharmaceutical product; and SCTT11 for the treatment of thyroid eye disease.
Sinocelltech Group Limited Fundamentals Summary
| 688520 fundamental statistics | |
|---|---|
| Market cap | CN¥19.37b |
| Earnings (TTM) | -CN¥564.85m |
| Revenue (TTM) | CN¥1.56b |
Is 688520 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 688520 income statement (TTM) | |
|---|---|
| Revenue | CN¥1.56b |
| Cost of Revenue | CN¥107.68m |
| Gross Profit | CN¥1.45b |
| Other Expenses | CN¥2.02b |
| Earnings | -CN¥564.85m |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
May 11, 2026
| Earnings per share (EPS) | -1.20 |
| Gross Margin | 93.10% |
| Net Profit Margin | -36.20% |
| Debt/Equity Ratio | 2,563.6% |
How did 688520 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/05/03 19:31 |
| End of Day Share Price | 2026/04/30 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Sinocelltech Group Limited is covered by 3 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| null null | China International Capital Corporation Limited |
| Ziyu He | China International Capital Corporation Limited |
| Yizheng Yang | China International Capital Corporation Limited |